Modified Vaccinia Ankara (MVA) vaccine platform: standardized template for collection of key information for risk/benefit assessment

The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features specifically of the MVA-BN vector system, followed by a template with details on the safety and characteristics of an MVA-BN-based vaccine against Zaire ebolavirus and other filovirus strains.

Access the publication here >